Navigation Links
Montclair Breast Center introduces 3D Mammography.

Montclair, NJ (PRWEB) May 02, 2013

Montclair Breast Center is one of the first women’s centers in New Jersey to offer 3D mammography (breast tomosynthesis) for breast cancer screening. Breast tomosynthesis produces a three-dimensional view of the breast tissue that helps radiologists identify and characterize individual breast structures without the confusion of overlapping tissue.

The center’s Selenia® Dimensions® breast tomosynthesis system is made by Hologic, a world leader in digital mammography. The Selenia Dimensions system offers exceptionally sharp breast images, an advanced ergonomic design providing more patient comfort, and the ground-breaking tomosynthesis platform designed to deliver superior screening and diagnostic performance.

Breast tomosynthesis will benefit all screening and diagnostic mammography patients, and is especially valuable for women receiving a baseline screening, those who have dense breast tissue and/or women with a personal history of breast cancer.

Breast cancer screening with tomosynthesis when combined with a conventional 2D mammography has a higher cancer detection rate than conventional 2D mammography alone.{1} Tomosynthesis technology gives radiologists increased confidence with a significant reduction in recall rates. {2}

The tomosynthesis screening experience is similar to a traditional mammogram. During a tomosynthesis exam, multiple, low-dose images of the breast are acquired at different angles. These images are then used to produce a series of one-millimeter thick slices that can be viewed as a 3D reconstruction of the breast.

Breast cancer is the second leading cause of cancer death among women, exceeded only by lung cancer. Statistics indicate that one in eight women will develop breast cancer sometime in her lifetime. The stage at which breast cancer is detected influences a woman’s chance of survival. If detected early, the five-year survival rate is 98 percent. {3}

Of patients who began and continued their screening at Montclair Breast Center and were diagnosed with breast cancer in 2012, 95% were diagnosed at the most treatable Stages 0 or 1. The national average for such early diagnosis in all women is just 60%. This extremely high rate of early detection reflects Montclair Breast Center’s breast imaging expertise, physician/patient collaboration, and attention to detail.

In offering breast tomosynthesis digital mammography, Montclair Breast Center provides the latest in imaging technology. If you would like to schedule a 3D mammogram or have questions about this important breast health procedure, please visit Montclair Breast Center, or call 973-509-1818.

About Montclair Breast Center: Montclair Breast Center is a premier, multidisciplinary breast center, specializing in proactive breast healthcare, risk-reduction techniques and the early detection and treatment of breast cancer. Our nationally recognized, dedicated team of breast imagers and breast surgeons use the most sophisticated technologies and are committed to providing better breast care than anywhere.

{1} Skaane P, Gullien R, Eben EB, et. al. Reading time of FFDM and tomosynthesis in a population-based screening program. Radiological Society of North America annual meeting. Chicago, Il, 2011.
{2} Hologic, Inc. FDA PMA submission P080003.
{3} Breast Cancer Facts & Figures 2011, American Cancer Society.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stereotactic Breast Biopsy introduced with Fischer-Giotto Image at American Society of Breast Surgeons course
2. Robert Lowen MD, Expert Bay Area Plastic Surgeon, Announces Cutting-Edge 3-D Crisalix Imaging Technology to Aid Patients in Choosing their Breast Implant Size
3. Patti Flint MD, A Top Female Plastic Surgeon in the Southwest, Is Proud To Offer Cutting-Edge 3D Crisalix Technology to Patients When Selecting Breast Implants
4. Dr. Vasquez at the Connecticut Plastic Surgery Group Now Offers the Unique Crisalix 3D Simulations for Facial Aesthetics and Breast Augmentation
5. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
6. The First Dedicated Breast Cancer Cell Line Transfection Reagent
7. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
8. University of Maryland Breast Cancer Research Pioneer Dr. Angela Brodie Appointed Fellow of New American Association for Cancer Research Academy
9. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
10. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
11. Frost & Sullivan: Modest Growth Projected in the U.S. Breast Imaging Systems Market Amidst Increasing Breast Cancer Prevalence
Post Your Comments:
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... ... 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for production, ... to serve as Chief Operating Officer. , Having joined InSphero in November ... and was promoted to Head of InSphero Diagnostics in 2014. There she has ...
(Date:11/24/2015)... , Nov. 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: ... , the company,s president and chief executive officer, will present ... next week in New York City . ... Tuesday, December 1, 2015 at 9:30 a.m. EST. ... to the website at least 15 minutes prior to the ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
Breaking Biology News(10 mins):